IP Library › Granted Patent US 12,252,747
Granted Patent B2
US 12,252,747 · App. 17/837,731 · Granted Mar 18, 2025

Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer

Inventors: David Frazier Jarrard (Madison, WI); Bing Yang (Madison, WI)
Assignee: Wisconsin Alumni Research Foundation
C12Q1/6886C12Q2600/154
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,252,747
App. No.
17/837,731
Granted
Mar 18, 2025
Kind
B2
Abstract

A method of detecting the presence of a prostate cancer field defect in a human subject comprising the step of (a) obtaining genomic DNA from the human subject and (b) quantitating methylation in at least one target region selected from the group consisting of CAV1, EVX1, MCF2L, FGF1, NCR2 and WNT2 and EXT1 and SPAG4 target, wherein significant methylation changes indicate the presence of prostate cancer or a prostate cancer field defect, wherein the change is relative to tissue from a second human subject who does not have prostate cancer.

Claims (24)

1. A method for detecting methylation in target DNA isolated from prostate tissue, a urine sample, or a semen sample from a subject, the method comprising:

providing a reaction mixture comprising: (1) the target DNA or (2) a bisulfite modified target DNA generated by bisulfite modifying the target DNA, wherein the target DNA comprises a target sequence selected from the group consisting of SEQ ID NOs: 1-6, 18, and 39 or an allele thereof; and

reacting the reaction mixture to carry out an assay that detects and quantifies methylation at one or more CpG sites within the target sequence.

2. The method of claim 1 , wherein the reaction mixture further comprises at least one primer specific for methylated sequences.

3. The method of claim 1 , wherein the reaction mixture further comprises at least one primer not specific for methylated sequences.

4. The method of claim 1 , wherein the reaction mixture further comprises at least one biotinylated primer.

5. The method of claim 1 , wherein the reaction mixture further comprises a pair of primers, and the reacting comprises amplifying the target DNA or the bisulfite modified target DNA with the pair of primers.

6. The method of claim 1 , wherein the reacting comprises pyrosequencing.

7. The method of claim 1 , wherein the reacting comprises methylation specific quantitative polymerase chain reaction.

8. The method of claim 1 , wherein the reaction mixture comprises the bisulfite modified target DNA.

9. The method of claim 8 , wherein the reacting comprises quantitative bisulfite sequencing.

10. The method of claim 1 , wherein the subject is a prostate cancer patient.

11. The method of claim 1 , wherein the target DNA is isolated from prostate tissue from the subject.

12. The method of claim 1 , wherein the target DNA is isolated from histologically normal prostate tissue from the subject.

13. The method of claim 1 , wherein the target DNA is isolated from a urine sample from the subject.

14. The method of claim 1 , wherein the target DNA is isolated from a semen sample from the subject.

15. The method of 1 wherein the target sequence is SEQ ID NO:1 or an allele thereof.

16. The method of 1 wherein the target sequence is SEQ ID NO:2 or an allele thereof.

17. The method of 1 wherein the target sequence is SEQ ID NO:3 or an allele thereof.

18. The method of 1 wherein the target sequence is SEQ ID NO:4 or an allele thereof.

19. The method of 1 wherein the target sequence is SEQ ID NO:5 or an allele thereof.

20. The method of 1 wherein the target sequence is SEQ ID NO:6 or an allele thereof.

21. The method of 1 wherein the target sequence is SEQ ID NO:18 or an allele thereof.

22. The method of 1 wherein the target sequence is SEQ ID NO:39 or an allele thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022
From: YANG, BING; JARRARD, DAVID
To: WISCONSIN ALUMNI RESEARCH FOUNDATION
Reel/Frame 060224/0184 →
Continuity (6)
Continuation 15970235 · May 3, 2018
Continuation 14226291 · Mar 26, 2014
Continuation In Part 13288607 · Nov 3, 2011
Provisional Application 61806566 · Mar 29, 2013
Provisional Application 61806218 · Mar 28, 2013
Related Publication 20220307091A1 · Sep 29, 2022
References Cited (85)
US 6872816B1 · Hall et al. · 2005 [cited by applicant]
US 6875572B2 · Prudent et al. · 2005 [cited by applicant]
US 6913881B1 · Aizenstein et al. · 2005 [cited by applicant]
US 7011944B2 · Prudent et al. · 2006 [cited by applicant]
US 20080081333A1 · Mori et al. · 2008 [cited by applicant]
US 20090263799A1 · Smith · 2009 [cited by examiner]
US 20090305234A1 · Olek et al. · 2009 [cited by applicant]
US 20090325868A1 · Liu · 2009 [cited by examiner]
US 20100131432A1 · Kennedy · 2010 [cited by examiner]
US 20100135877A1 · Watanabe · 2010 [cited by applicant]
US 20100273151A1 · Tapscott · 2010 [cited by examiner]
US 20120046346A1 · Rossi · 2012 [cited by examiner]
US 20120135877A1 · Jarrard · 2012 [cited by applicant]
US 20140296355A1 · Jarrard et al. · 2014 [cited by applicant]
WO WO200070090A1 · 2000 [cited by applicant]
WO WO2002072880A2 · 2002 [cited by applicant]
International Search Authority, Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration; International App. No. PCT/US2014/0319… [cited by applicant]
Adami, H.-O., The prostate cancer pseudo-epidemic, Acta Oncologica 49, 298-304. [cited by applicant]
Agnieszka et al., Aberrant epigenetic modifications in the CTCF binding domain of the IGF2/H19 gene in prostate cancer compared with benign prostate hyperplasia, (2009) International Journal of Oncology 35, 87-96. [cited by applicant]
Aitchison, A., et al. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues, Prostate 67, 638-644 (2007). [cited by applicant]
Ananthanarayanan V., et al., Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): association with diagnosis of prostate cancer, Prostat… [cited by applicant]
Ayala, A.G. et al., Prostatic Intraepithelial Neoplasia: Recent Advances, Archives of Pathology & Laboratory Medicine 131, 1257-1266 (2007). [cited by applicant]
Bhusari, S., et al., Insulin-like growth factor-2 (IGF2) loss of imprinting marks a field defect within human prostates containing cancer, The Prostate, Mar. 22, 2011. [cited by applicant]
Braakhuis, B.J.M., et al. Genetic Explanation of Slaughter's Concept of Field Cancerization, Cancer Research 63, 1727-1730 (2003). [cited by applicant]
Bird, A. DNA methylation patterns and epigenetic memory, Genes Dev 16, 16 (2002). [cited by applicant]
Brooks et al. Prostate cancer screening 2010: updated recommendations from the American Cancer Society (2010) J.Natl.Med.Assoc. 102(5), 423-429. [cited by applicant]
Campan M., et al. MethyLight. Methods Mol.Biol. 2009;507:325-37. [cited by applicant]
Chandran et al., Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors, (2005) BMC Cancer 5, 45. [cited by applicant]
Clark, S.J., Action at a distance: Epigenetic silencing of large chromosomal regions in carcinogenesis, Human Molecular Genetics 16, R88-R95 (2007). [cited by applicant]
Cooper, C.S. et al., Concepts of epigenetics in prostate cancer development, Br J Cancer 100, 240-245 (2008). [cited by applicant]
Cottrell S.E., et al., A real-time PCR assay for DNA-methylation using methylation specific blockers, Nucleic Acids Res. 2004; 32(1): e10. [cited by applicant]
Cui et al., Hypermethylation of theCaveolin-1 Gene Promoter in Prostate Cancer, The Prostate 46:249-256 (2001). [cited by applicant]
Darst R.P., Bisulfite sequencing of DNA. Curr Protoc Mol Biol. Jul. 2010; Chapter 7:Unit 7.9.1-17. [cited by applicant]
Djavan B, et al. Optimal predictors of prostate cancer on repeat prostate biopsy: A prospective study of 1,051 men, J.Urol. Apr. 2000.;163(4):1144-8. [cited by applicant]
Diffenbach, PCR methods and Applications (1993) vol. 3, pp. S30-S37. [cited by applicant]
Eads C.A., MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res. Apr. 15, 2000; 28(8):E32. [cited by applicant]
Eastham, J.A., et al. (2007) Prognostic Significance of Location of Positive Margins in Radical Prostatectomy Specimens, Urology 70, 965-969. [cited by applicant]
Fatemi, M., et al., Footprinting of mammalian promoters: use of a CpG DNA methyltransferase revealing nucleosome positions at a single molecule level, Nucleic Acids Research 33, e176. [cited by applicant]
Feinberg, A.P., Ohlsson, R. & Henikoff, S., The epigenetic progenitor origin of human cancer, Nat Rev Genet 7, 21 33 (2006). [cited by applicant]
Fu VX, et al., Aging and cancer-related loss of insulin-like growth factor 2 imprinting in the mouse and human prostate, Cancer Res. Aug. 15, 2008;68(16):6797-802. [cited by applicant]
Fujita K., et al., Specific detection of prostate cancer cells in urine by multiplex immunofluorescence cytology, Hum.Pathol. Jul. 2009;40(7):924-33. [cited by applicant]
Gann et al., Risk factors for prostate cancer detection after a negative biopsy: A novel multivariable longitudinal approach (2010) JCO 28, 7. [cited by applicant]
Garcia, S.B., et al. Field cancerization, clonality, and epithelial stem cells: the spread of mutated clones in epithelial sheets, The Journal of Pathology 187, 61-81 (1999). [cited by applicant]
Gu H., et al., Preparation of reduced representation bisulfite sequencing libraries for genome-scale DNA methylation profiling, Nat. Protoc. Apr. 2011;6(4):468-81. [cited by applicant]
Hanson, J.A., et al., Gene Promoter Methylation in Prostate Tumor-Associated Stromal Cells, J. Natl. Cancer Inst. 98, 255-261 (2006). [cited by applicant]
Henrique, R., et al., Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis, Mol Cancer Res 4, 1-8 (2006). [cited by applicant]
Hu, M., et al. Distinct epigenetic changes in the stromal cells of breast cancers, Nat Genet 37, 899-905 (2005). [cited by applicant]
Jemal et al., Cancer Statistics, 2009 (2009) CA Cancer J Clin 59, 225-249. [cited by applicant]
Jemal, et al., Cancer statistics, 2010. CA Cancer J.Clin. Sep. 2010;60(5):277-300. [cited by applicant]
Jothy et al. (1996) Field effect of human colon carcinoma on normal mucosa: relevance of carcinoembryonic antigen expression. Tumour Biol 17, 7. [cited by applicant]
Katz DA, et al., Health perceptions in patients who undergo screening and workup for prostate cancer, Urology Feb. 2007;69(2):215-20. [cited by applicant]
Kim, Y. Cutaneous T-cell lymphoma (CTCL) responses to a TLR9 agonist CPG immunomodulator (CPG 7909), a phase I study (2004) Journal of Clinical Oncology 22(14):6600. [cited by applicant]
Mathers JC, et al., Induction of epigenetic alterations by dietary and other environmental factors, Adv Genet. 71, 37 (2010). [cited by applicant]
Matthew Truong, et al.; “Using the Epigenetic Field Defect to Detect Prostate Cancer in Biopsy Negative Patients”, The Journal of Urology, vol. 189, No. 6, Nov. 15, 2012, XP055141138, ISSN: 0022-5347, DOI:10.1016/j.juro… [cited by applicant]
Mehrotra, J., et al., Quantitative, spatial resolution of the epigenetic field effect in prostate cancer, Prostate 68, 152-160 (2008). [cited by applicant]
Miyazato, et al. (1999) Microsatellite instability in double cancers of the esophagus and head and neck, Diseases of the Esophagus 12, 132-136. [cited by applicant]
Mouraviev, V., et al. Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer, Cancer 110, 906-910 (2007). [cited by applicant]
Nelson et al., Epigenetic alterations in human prostate cancers (2009) Endocrinology 150, 3991-4002. [cited by applicant]
Nonn et al., Evidence for field cancerization of the prostate (2009) Prostate 69, 1470-1479. [cited by applicant]
Park, Promoter hypermethylation in prostate cancer, Cancer Control 17, 11. [cited by applicant]
Richardson, B.C., Role of DNA Methylation in the Regulation of Cell Function: Autoimmunity, Aging and Cancer, The Journal of Nutrition 132, 2401S-2405S (2002). [cited by applicant]
Rogers C.G., et al., High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection, J.Urol. Nov. 2006;176(5):2280-4. [cited by applicant]
Roux et al. PCR Methods and Applications (1995) vol. 4, pp. s185-s194. [cited by applicant]
Saeed AI, et al., TM4 microarray software suite, Methods in Enzymology 411, 60 (2006). [cited by applicant]
Saxonov, S., Berg, P. & Brutlag, D.L., A genome-wide analysis of CpG dinucleotides in the human genome distinguishes two distinct classes of promoters, Proceedings of the National Academy of Sciences of the United State… [cited by applicant]
Schroder et al., Screening and prostate-cancer mortality in a randomized European study (2009) The New England Journal of Medicine 360. [cited by applicant]
Schulz, W.A. et al. Epigenetic mechanisms in the biology of prostate cancer, Semin Cancer Biol 19, 172-180 (2009). [cited by applicant]
Slaughter D.P., Southwick H.W., Smejkal, W.; Field cancerization in oral stratified squamous epithelium; Clinical implications of multicentric origin, Cancer 6, 6 (1953). [cited by applicant]
Stephenson A.J., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era, J.Clin.Oncol. Sep. 10, 2009;27(26):4300-5. [cited by applicant]
Strope SA, et al., Prostate cancer screening: Current status and future perspectives, Nat.Rev.Urol. Sep. 2010;7(9):487-93. [cited by applicant]
Suzuki, K., et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage, Cancer Cell 9, 199-207 (2006). [cited by applicant]
Takahashi, T., et al. (1998) Clonal and Chronological Genetic Analysis of Multifocal Cancers of the Bladder and Upper Urinary Tract, Cancer Research 58, 5835-5841. [cited by applicant]
Thompson et al., Prevalence of prostate cancer among men with a prostate specific antigen level ≤4.0 ng per milliliter (2004) N Engl J Med 350, 2239-2246. [cited by applicant]
Tost, et al., Serial pyrosequencing for quantitative DNA methylation, BioTechniques, 40, 6 (2006). [cited by applicant]
Truong et al., “Using the Epigenetic Field Defect to Detect Prostate Cancer in Biopsy Negative Patients” (2012) J Urol. [cited by applicant]
Ushijima, T. (2007) Epigenetic Field for Cancerization, Journal of Biochemistry and Molecular Biology, vol. 40, No. 2, Mar. 2007, pp. 142-150 40, 9. [cited by applicant]
Walker et al., Methods in Molecular Biology, Epigenetic Protocols, Second Edition, Department of Biology University of Alabama at Birmingham, Published by Human Press, 2011. [cited by applicant]
Weber, M., et al. Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nat Genet 37, 853-862 (2005). [cited by applicant]
Wolff, E.M., et al., Unique DNA Methylation Patterns Distinguish Noninvasive and Invasive Urothelial Cancers and Establish an Epigenetic Field Defect in Premalignant Tissue, Cancer Research 70, 8169-8178. [cited by applicant]
Yanatatsaneejit P et al., Promoter hypermethylation of CCNA1, RARRES1, and HRASLS3 in nasopharyngeal carcinoma, Oral Oncol., 2008, 44(4):400-406. [cited by applicant]
Yang B, Bhusari S, Kueck J, Weeratunga P, Wagner J, Leverson G, Huang W, Jarrard DF. Methylation profiling defines an extensive field defect in histologically normal prostate tissues associated with prostate cancer. Neo… [cited by applicant]
Yoshida et al., Prostate-specific antigen activates single-chain urokinase-type plasminogen activator, International Journal of Cancer, 63(6):863-865. [cited by applicant]
“The Polymerase Chain Reaction,” published by Integrated DNA Technologies, 2005 and 2011 (no known author). [cited by applicant]
U.S. Appl. No. 15/970,235, David Frazier Jarrard, filed May 3, 2018. [cited by applicant]
U.S. Appl. No. 14/226,291, David Frazier Jarrard, filed Mar. 26, 2014. [cited by applicant]